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Background: We sought to determine whether heart rate variability (HRV), blood pressure (BP) variability, and
baroreceptor-heart rate reflex sensitivity can be reliably assessed using finger volume pulse waveforms obtained
from the commercially available EndoPAT device.
Methods: Non-invasive BP (Finometer Pro as a non-invasive standard) and finger volume (EndoPAT) waveforms
were recorded in 65 adults (37 ± 14 years; 60% female) and systolic BP and heart rate (HR) time series were derived
after calibrating the EndoPAT signal based on systolic and diastolic BP values obtained by a sphygomomanometer.
Transfer function analyses were performed to test for coherence between systolic BP and HR time series derived
from the Finometer and EndoPAT devices. Time-domain HRV parameters, frequency domain HR and systolic BP
variability parameters, and baroreflex sensitivity (sequence technique) were computed from Finometer- and
EndoPAT-derived time series and intraclass correlation coefficients (ICC) were calculated.
Results: Squared coherence between systolic BP time series derived from the Finometer and EndoPAT devices was
low, suggesting poor correlation. In contrast, squared coherence between HR time series derived from the two
devices was excellent [High Frequency (HF) = 0.80, Low Frequency (LF) = 0.81], with gain values close to 1.0. ICC values
for time- and frequency-domain HRV parameters were excellent (>0.9 except for relative HF HRV, which was 0.77), while
ICC values for frequency-domain BP variability parameters and baroreceptor-HR reflex sensitivity were low.
Conclusions: Finger volume pulse waveforms can be used to reliably assess both time-domain and frequency-domain
HR variability. However, frequency domain BP variability parameters cannot be reliably assessed from finger volume
pulse waveforms using the simple calibration technique used in this study.
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Autonomic regulation of heart rate (HR) and blood pres-
sure (BP) is commonly cited as an indicator of cardiovascu-
lar health in humans [1-4]. Time- and frequency-domain
HR variability (HRV) provide reliable estimates of both
sympathetic and parasympathetic modulation of cardiac
function [2,3,5,6], while low frequency BP variability (BPV)
reflects sympathetic modulation of vascular tone [4,7,8].* Correspondence: jess-fiedorowicz@uiowa.edu
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unless otherwise stated.Baroreceptor-HR reflex sensitivity is another common
measure of cardio-autonomic health, providing insight
into cardiovascular regulation by the baroreceptors [9,10].
Time-domain HRV can be reliably assessed by deriving
the standard deviation of NN intervals (SDNN) and the
root-mean-square of successive differences (RMSSD) from
normal sinus rhythm pulse intervals (NN). SDNN is the
standard deviation of all NN intervals over a fixed amount
of time, usually 5-minutes [1,3]. NN intervals are the mea-
sured intervals between consecutive heartbeats originating
from a sinus rhythm. SDNN is an indicator of both sym-
pathetic and parasympathetic cardiac inputs, and is thus aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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HRV. RMSSD is the square root of the mean of the squared
differences between successive NN intervals. RMSSD is
considered to reflect mainly parasympathetic and less
sympathetic modulation of cardiac function [1].
Spectral analysis can be used to decompose oscillatory
components of HRV and BPV into high frequency (HF),
low frequency (LF), and very low frequency (VLF) bands.
For HRV, the HF range (0.15-0.4) is representative of
respiration-linked parasympathetic cardiac modulation,
LF (0.06-0.15) is considered to be indicative of both
parasympathetic and sympathetic modulation, and VLF
(0.02-0.06) is sometimes considered representative of
sympathetic cardiac modulation, but its true physio-
logic/pathophysiologic role is unclear [1,2,7]. For BPV in
humans, the HF (0.15-0.4) component is largely dependent
on respiration-linked fluctuations in stroke volume
possibly caused by respiratory mechanics. LF BPV (0.075-
0.15) is mostly representative of sympathetic modulation
of vascular tone, while VLF BPV (0.02-0.07) results
from several mechanisms, including myogenic vascular
control and endocrine factors (e.g., renin-angiotensin
system) [4,8,11].
In this study, we sought to validate the measurements
obtained from a commercially available EndoPAT device
(Itamar Medical Ltd., Caesarea, Israel) using finger
volume pulse waveforms to derive HRV and BPV param-
eters and to estimate baroreceptor-HR reflex sensitivity.
BP waveforms obtained from a commercially available Fin-
ometer Pro device (Finapres Medical Systems, Amsterdam,
The Netherlands) were used to validate the EndoPAT-
derived HRV and BPV parameters and baroreceptor-HR
reflex sensitivity. The EndoPAT device measures arterial
pulsatile volume changes in the fingertips by plethysmog-
raphy. This reportedly allows assessment of arterial dilator
capability, suggested to be an indicator of overall cardiovas-
cular health [12]. This technology has the potential to
allow non-invasive measurement of HRV and BPV, how-
ever has yet to be validated for these uses. The EndoPAT
device provides waveforms that potentially allow for
reliable beat-by-beat HR and BP trends to be derived
and subsequently used for HRV, BPV, and baroreflex
analyses. The Finometer Pro, a non-invasive BP moni-
toring system, evaluates finger arterial BP measure-
ments detected by an infrared photoplethysmograph
and a finger pressure cuff. The Finometer Pro can be used
as a non-invasive standard for measuring HRV and BPV
in humans [13,14]. The Finometer Pro and related ma-
chines have been validated in a wide variety of patient
populations for HRV, BPV and baroreflex analyses [15-17].
We hypothesized that the EndoPAT finger volume
pulse waveforms would provide reliable estimates for
both time-domain and frequency-domain HRV. We also




The protocol was approved by the Institutional Review
Board at the University of Iowa and was conducted in
compliance with the Declaration of Helsinki. Partici-
pants were recruited using a University-wide email and
a local print advertisement at the University of Iowa
Hospitals and Clinics. Participants were excluded if they
had significant hand injuries. All participants were asked
to abstain from food, caffeine, and tobacco for two hours
before each visit. We obtained informed consent from
each participant, and a member of the research team
assessed history of illness, recreational drug exposure,
alcohol exposure, and tobacco exposure (pack per day*-
years). Alcohol exposure was assessed using the AUDIT-
C screener [18], and participants were classified as either
positive or negative for alcohol misuse. Men were classi-
fied under alcohol misuse following an AUDIT-C result
of 4 or higher, while women were classified under alco-
hol misuse following an AUDIT-C result of 3 or higher.
HRV, BPV, and baroreflex assessment
For all participants, BP waveforms were recorded non-
invasively in the middle finger of the left hand for
30 minutes at a sampling rate of 200 Hz using the
Finometer Pro device (non-invasive “gold standard”).
Simultaneously, finger volume pulse waveforms were
also recorded in the index fingers of both hands non-
invasively using the EndoPAT device, sampling at a
frequency of 128 Hz. Only the EndoPAT recordings for
the left hand were used for subsequent analyses. The
non-calibrated finger volume pulse waveforms were
calibrated so that the average systolic peaks and diastolic
troughs of the 30-minute waveforms corresponded to
the systolic and diastolic BP values obtained using a
sphygmomanometer at the beginning of the protocol.
From these waveforms, systolic BP and heart rate were
derived using the Analyzer module of the freely avail-
able HemoLab software (http://www.haraldstauss.com/
HaraldStaussScientific/hemolab/default.html) on a beat-
by-beat basis. HR and systolic BP were derived from
the calibrated EndoPAT waveform. From this signal,
beat-by-beat trends in heart rate and systolic BP were de-
rived in the HemoLab software analyzer module. The Fin-
ometer provided an automatically derived trend for both
HR and BP. No filters were used during data acquisition
or subsequent data analysis.
Heart rate and systolic BP values affected by recording
artifacts or cardiac arrhythmias were visually detected
and replaced by interpolated values. The following ana-
lysis was performed using the Batch Processor module





Entire sample 2.6 (7.6)
Smokers only 12.4 (12.5)
Body mass index (kg/m2) 27.9 (6.5)
Heart rate (bpm) 70.9 (13)
Systolic blood pressure (mmHg) 119.5 (13.0)
Diastolic blood pressure (mmHg) 74.9 (8.6)
Respiratory rate (min−1) 13.4 (3)
N (%)
Female gender 39 (60%)
White, not hispanic 61 (93.8%)
Unmarried 32 (48%)
Unemployed 3 (4.6%)
Alcohol misuse 31 (47%)
History of tobacco use 14 (22%)
Heart attack 1 (1.5%)
High blood pressure 9 (13.6%)
Diabetes or high blood sugar 4 (6%)
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were calculated from the beat-by-beat HR time series
using a stationary artifact free segment of 5-minute dur-
ation. For frequency-domain analysis, the beat-by-beat
systolic BP and HR time series were interpolated (cubic
spline) to obtain equidistant time series at 10 Hz sampling
rate. Absolute and relative (absolute spectral power
divided by total spectral power) spectral powers were
calculated in the VLF (0.02-0.05 Hz) [2,4], LF (0.05-
0.15 Hz), and HF (0.15-0.50 Hz) bands by applying the
fast Fourier transform (FFT, ~410 s long segments, 50%
overlap) to the full 30 minute long time series. Time-
domain analysis was limited to 5-minute segments, as
recommended [1], because duration affects the size of the
results in time-domain analysis. Results from frequency-
domain analysis, on the other hand, are not affected by
duration of the segments analyzed.
Baroreceptor-heart rate reflex sensitivity was calcu-
lated from the 30 minute Finometer-derived BP and
EndoPAT-derived calibrated finger volume pulse wave-
forms using the sequence technique implemented in the
Analyzer module of the HemoLab software. The entire
recording was selected for analysis of each device, separ-
ately. Systolic BP was analyzed using the “Calculate-
Baroreflex” function with an “R for inclusion” of 0.8. A
delay of three heartbeats was selected between the beat-
by-beat systolic BP and pulse interval values.
Transfer function analysis
In order to assess the correlation between Finometer-
derived and EndoPAT-derived time series, transfer func-
tion analysis was performed that provides the squared
coherence and the gain between the two time series. The
squared coherence provides values (between 0 and 1)
similar to the R2 value of a correlation analysis for each
frequency component of the two time series. The gain of
the transfer function can be seen as a factor by which each
frequency component of one time series is amplified (gain
>1.0) or reduced (gain <1.0) compared to the other time
series. Transfer function analysis was performed from the
spline interpolated (10 Hz) systolic BP time series derived
from the EndoPAT- and Finometer-derived waveforms.
The same protocol was performed for the HR time
series derived from both respective machines. The squared
coherence function γ(q) and gain H(q) of the transfer
functions were calculated on the basis of the autospectral
density functions and the cross-spectrum of the input
(Finometer-derived time series) and output (EndoPAT-
derived) functions. This was done using the Batch pro-
cessor module of the HemoLab software.
Subsequently, the maximum gain and coherence values
for both the HF and LF spectral domains were calculated
for each participant. This was done for the transfer func-
tions calculated from both the HR and BP time series.Due to systematic detection of cardiac arrhythmias, four
participants were excluded from the transfer function
analysis.
Statistical analyses
Data are presented as mean ± SD. Study data were
collected and managed using REDCap (Research Elec-
tronic Data Capture) tools hosted at The University of
Iowa Hospitals and Clinics. Data was merged using
SAS 9.3 (SAS Institute Inc., Cary, NC) and descriptive
statistics for the sample were compiled. Intraclass cor-
relation coefficients between parameters derived from
Finometer-(BP) and EndoPAT-derived (finger volume
pulse) waveforms were calculated using SPSS Statistics
19.0 (IBM Corp. Armonk, NY). Bland-Altman plots
were created using SigmaPlot 12.0 (Systat Software,
San Jose, CA) to display agreement across the range of
observed values.
Results
Sociodemographic and clinical characteristics of our
sample are outlined in Table 1. The sample had a mean
(SD) age of 37 (14) and was 60% female.
Transfer function analysis (Table 2) revealed that squared
coherence for systolic BP time series derived from the
Finometer and EndoPAT devices was relatively low
(<0.35) for the LF and HF bands. This finding indicates
Table 2 Transfer function analysis between finometer-
and EndoPAT-derived time series
Low frequency High frequency
Mean(SD) Coherence Gain Coherence Gain
Systolic BP 0.33 (0.13) 0.90 (0.45) 0.27 (0.08) 0.55 (0.34)
HR 0.81 (0.17) 0.94 (0.14) 0.80 (0.17) 1.03 (0.22)
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from the Finometer and EndoPAT devices. As a result
of the low squared coherence, we don’t feel that the gain
values can be interpreted in a meaningful way.
In contrast to systolic BP, the squared coherence for
the HR time series derived from the two devices was
high (HF = 0.80, LF = 0.81), indicating excellent agree-
ment between Finometer- and EndoPAT- derived HR
time series. In addition, the gain ~1.0 indicates that the
HR values correspond in absolute terms.
Results of our primary analysis are summarized in
Table 3. Intraclass correlation coefficients (ICC) for time-
domain HRV showed a strong association for both SDNN
(0.99) and RMSSD (0.96). Frequency-domain HRV showed
similarly strong ICCs for both absolute and relative mea-
sures of VLF, LF, and HF spectral powers (ranging from
0.77 to 0.97, Table 3). The frequency domain BPV analysis
garnered much weaker ICCs than HRV analysis with ICC
values ranging from 0.34 to 0.64 (Table 3).
Baroreceptor-heart rate reflex sensitivity values derived
from the two waveforms were not well correlated (ICC =
0.27). From the EndoPAT-derived time series, only 4.5 (SD
4.0) baroreflex sequences were detected per 1000 heart-
beats compared to 6.1 (8.0) sequences per 1000 heart
beats detected in the Finometer-derived time series.
However, this difference in number of sequences was not
significant (Wilcoxon Signed Rank S = −211, p = 0.16).
EndoPAT-derived time series tended to overestimate baro-
reflex gain relative to the Finometer-derived time series
[mean (SD)] 23.9 (12.0) ms/mmHg vs. 15.7 (8.2) ms/mmHg
and EndoPAT-derived baroreflex gains did not appear
to reliably correlate to the Finometer-derived gains
(ICC = 0.27, 95% C.I. 0.02-0.49).
Comparison by Bland-Altman plots supported the re-
sults obtained by transfer function analysis and intra-class
correlation analysis, indicating that EndoPAT and Fin-
ometer provide similar results for both time - (Figure 1)
and frequency-domain (Figure 2) HRV parameters, across
the range of observed values. For all frequency domain
BPV parameters (Figure 3), the Bland-Altman plots demon-
strated poor agreement between Finometer- and EndoPAT-
derived values.
Discussion
The aim of this study was to investigate if HR and sys-
tolic BP time series derived from finger volume pulsewaveforms provided by the EndoPAT device allow for
reliable estimation of HRV and BPV parameters. As a
validated standard, HR and systolic BP time series
obtained from the Finometer device were used. To in-
vestigate if the EndoPAT-derived HR and systolic BP
time series correspond to the time series derived from
the Finometer device, transfer function analysis was
performed. The squared coherence of the transfer func-
tion revealed excellent correlation between the HR time
series derived from the two devices but indicated poor
correlation for the systolic BP time series. Even without
looking at the actual HRV and BPV parameters, this
finding already indicates that HRV parameters may be
reliably derived from waveforms provided by the Endo-
PAT device, while it is highly questionable if systolic
BPV can be reliably assessed from the finger volume
pulse waveforms. To some degree, this result was
expected, as the pulse-synchronous oscillatory pattern
of the finger volume pulse waveform should allow for
reasonably accurate determination of inter-beat inter-
vals. However, the waveform of the finger volume pulse
is distorted relative to the standard pressure waveform
provided by the Finometer device and, thus, accurate
determination of beat-by-beat systolic BP may not be
possible using a simple calibration procedure based on
sphygmomanometer-derived BP values.
Measures of SDNN and RMSSD, as well as VLF, LF,
and HF spectral HRV derived from the EndoPAT wave-
forms, were all in strong agreement (high ICC values)
with these parameters derived from the Finometer wave-
forms. The ICC value for relative HF spectral power of
HRV (0.77) was not as high as for VLF and LF HRV
(0.94 and 0.92) but still significant. While spectral pa-
rameters of BPV derived from the EndoPAT device did
not correlate well with BPV parameters derived from the
Finometer, the ICC value for relative LF BPV was in the
acceptable range (0.64). However, given the low LF
coherence between systolic BP time series derived from
EndoPAT and Finometer, this ICC value of 0.64 should
be considered cautiously and may not indicate that rela-
tive LF spectral power of systolic BP can be reliably
derived from EndoPAT-derived waveforms.
The ICC value for baroreflex sensitivity was even less
than the ICC value for BPV. The low ICC value we
observed for the baroreflex gain suggests that time series
derived from the EndoPAT device do not reliably assess
baroreflex function. Baroreflex analysis based on EndoPAT-
derived waveforms tended to overestimate baroreflex
sensitivity, and only detected approximately two thirds
of the baroreflex sequences detected by Finometer-
derived waveforms.
The current study is not without limitations. Both
machines, to allow for simultaneous recordings, were
applied to the same hand — whereas in a typical use,
Table 3 Intraclass correlation coefficients for primary outcomes
Measures Intraclass correlation coefficients between EndoPAT and finometer
95% Confidence interval
ICC Lower bound Upper bound
SDNN 0.99 0.98 0.99
RMSSD 0.96 0.94 0.98
Absolute VLF of HRV 0.94 0.90 0.96
Relative VLF of HRV 0.94 0.90 0.96
Absolute LF of HRV 0.94 0.90 0.96
Relative LF of HRV 0.92 0.87 0.95
Absolute HF of HRV 0.97 0.95 0.98
Relative HF of HRV 0.77 0.65 0.86
Absolute VLF of BPV 0.34 0.11 0.54
Relative VLF of BPV 0.37 0.14 0.56
Absolute LV of BPV 0.43 0.20 0.61
Relative LF of BPV 0.64 0.47 0.77
Absolute HF of BPV 0.57 0.38 0.71
Relative HF of BPV 0.51 0.31 0.67
Baroreflex gain 0.27 0.02 0.49
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However, this did not cause any discernible disruption
in the signals. Pulses may differ across digits. Addition-
ally, signals for both machines were not recorded in
unison and were sampled at different frequencies. These
design issues might contribute to discrepancies between
recordings from the two machines, which if anything
would bias the observed correlation to an underesti-
mate. Thus, the correlation between measures can be
assumed to be at least as strong as our study indicates.
HRV from electrocardiography was not available for
comparison, though HRV measures from both instru-
ments were highly consistent with each other. TheFigure 1 Bland-Altman plots of time domain HRV parameters derived
between EndoPAT- and Finometer-derived heart rate time series shows a h
SDNN and RMSSD.EndoPAT device includes a high-pass filter, the fre-
quency of which is not provided, which may impact
variability measures on spectral analysis, especially in
the VLF range. Although the age range of our adult co-
hort spanned a broad range and included a balance of
male and female participants, they were young and pre-
dominantly Caucasian, therefore caution should be used
when extrapolating our findings to other ethnicities.
While time domain parameters for HRV are generally
accepted to have high inter- and intra-visit reproducibil-
ity, spectral measurements have been shown to be less
reproducible between visits [19], and may thus be less
useful clinically.from EndoPAT and Finometer devices. Bland-Altman comparison
igh agreement between the two devices for the measurement of
Figure 2 Bland-Altman plots of frequency domain HRV parameters derived from EndoPAT and Finometer devices. Bland-Altman
comparison of frequency domain HRV parameters between EndoPAT- and Finometer-derived time series shows a high agreement between the
two devices— across VLF, LF, and HF spectral ranges for both absolute and relative HRV.
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http://www.biomedcentral.com/1471-2261/14/180Even though the conclusion of this study is that parame-
ters that depend on accurate BP waveforms, such as BPV
or baroreflex function, cannot be reliably determined from
the EndoPAT signal, one may speculate that it may be pos-
sible to design more advanced mathematical algorithmsthat may potentially be able to convert the finger volume
pulse from the EndoPAT device into a BP waveform. E.g.,
a transfer function may be derived from the EndoPAT and
Finometer recordings obtained in this study that may
potentially allow for reconstruction of a more or less
Figure 3 Bland-Altman plots of spectral domain BPV parameters derived from EndoPAT and Finometer devices. Bland-Altman comparison of
frequency-domain BPV parameters between EndoPAT- and Finometer-derived time series shows low agreement between the two devices— across
VLF, LF, and HF spectral ranges for both absolute and relative BPV. However, relative LF and absolute HF BPV demonstrate greater accuracy relative to
other BPV measures.
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http://www.biomedcentral.com/1471-2261/14/180accurate BP waveform from the finger volume pulse
signal provided by the EndoPAT device. However, such
analysis is beyond the scope of this study. Similarly, our
study is not applicable to the calculation of variability
between routine BP readings in the clinic [20].Conclusions
In summary, our findings support the hypothesis that
HRV can be reliably assessed by analysis of the raw Endo-
PAT signal (i.e., finger volume pulse waveforms), which
may allow researchers to assess cardiovascular/autonomic
Linder et al. BMC Cardiovascular Disorders 2014, 14:180 Page 8 of 8
http://www.biomedcentral.com/1471-2261/14/180health in addition to the manufacturer’s primary use
which is to measure microvascular endothelial func-
tion. In contrast, the BP variability derived from the
EndoPAT device showed low agreement with the mea-
surements obtained from the Finometer, suggesting
that the EndoPAT should not be used to assess BP vari-
ability. Still, while the EndoPAT may not be cost effect-
ive to use solely for HRV analysis, it may prove useful
to employ the device for measuring HRV in subjects on
which the device has already been used to assess endo-
thelial function (i.e., retrospective analysis of existing
recordings).
Abbreviations
BP: Blood pressure; BPV: Blood pressure variability; FFT: Fast fourier transform;
HF: High frequency; HRV: Heart rate variability; ICC: Intraclass correlation
coefficient; LF: Low frequency; NN: Normal sinus rhythm pulse intervals;
RMSSD: Root-mean-square of successive differences; SDNN: Standard eviation
of NN intervals; VLF: Very low frequency.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JRL, NHV, WGH, and JGF designed the study. NHV provided the Finometer
and JGF provided the EndoPAT. JGF funded the study, which was conducted
in his lab. JRL and HG recruited participants and collected the data. JRL
performed the analyses of HRV and BPV with assistance from HMS. JGF
performed the statistical analysis. JRL, HMS, GLP, NHV, WGH, JGF were
involved in interpreting the analyses. JRL and JGF drafted the manuscript,
which was edited with co-authors. All authors read and approved the final
manuscript.
Acknowledgements
Dr. Fiedorowicz is supported by the National Institutes of Health
(K23MH083695, P01HL014388). William G. Haynes is currently employed by
the Novartis Institute for Biomedical Research, Inc., Cambridge Massachusetts
and was faculty at the University of Iowa at the time the study was
conducted.
Author details
1Department of Internal Medicine, The University of Iowa, Iowa City, IA
52242, USA. 2Department of Pediatrics, The University of Iowa, Iowa City, IA
52242, USA. 3Department of Psychiatry, Roy J. and Lucille A. Carver College
of Medicine, The University of Iowa, Iowa City, IA 52242, USA. 4Institute for
Clinical and Translational Science, The University of Iowa, Iowa City, IA 52242,
USA. 5Department of Health and Human Physiology, College of Liberal Arts &
Sciences, The University of Iowa, Iowa City, IA 52242, USA. 6Department of
Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA
52242, USA. 7College of Pharmacy, The University of Iowa, Iowa City, IA
52242, USA. 8200 Hawkins Drive W278GH, Iowa City, IA 52242-1057, USA.
Received: 27 June 2014 Accepted: 26 November 2014
Published: 9 December 2014
References
1. Malik M, Bigger JT, Camm AJ, Kleiger RE, Malliani A, Moss AJ, Schwartz PJ:
Heart rate variability: Standards of measurement, physiological
interpretation, and clinical use. Task Force of the European Society of
Cardiology and the North American Society of Pacing and
Electrophysiology. Eur Heart J 1996, 17(3):354–381.
2. Cavalcanti S, Severi S, Chiari L, Avanzolini G, Enzmann G, Bianco G, Panzetta G:
Autonomic nervous function during haemodialysis assessed by spectral
analysis of heart-rate variability. Clin Sci (Lond) 1997, 92(4):351–359.
3. Ewing DJ, Borsey DQ, Bellavere F, Clarke BF: Cardiac autonomic neuropathy in
diabetes: comparison of measures of R-R interval variation. Diabetologia
1981, 21(1):18–24.4. Stauss HM: Identification of blood pressure control mechanisms by
power spectral analysis. Clin Exp Pharmacol Physiol 2007, 34(4):362–368.
5. Pagani M, Lombardi F, Guzzetti S, Rimoldi O, Furlan R, Pizzinelli P, Sandrone G,
Malfatto G, Dell'Orto S, Piccaluga E, Turiel M, Baselli G, Cerutti S, Malliani A:
Power spectral analysis of heart rate and arterial pressure variabilities as a
marker of sympatho-vagal interaction in man and conscious dog. Circ Res
1986, 59(2):178–193.
6. Sandercock GR, Bromley P, Brodie DA: Reliability of three commercially
available heart rate variability instruments using short-term (5-min)
recordings. Clin Physiol Funct Imaging 2004, 24(6):359–367.
7. Latalova K, Prasko J, Diveky T, Grambal A, Kamaradova D, Velartova H,
Salinger J, Opavsky J: Autonomic nervous system in euthymic patients
with bipolar affective disorder. Neuro Endocrinol Lett 2010, 31(6):829–836.
8. Parati G, Saul JP, Di Rienzo M, Mancia G: Spectral analysis of blood pressure
and heart rate variability in evaluating cardiovascular regulation. A critical
appraisal. Hypertens 1995, 25(6):1276–1286.
9. Parati G: Arterial baroreflex control of heart rate: determining factors and
methods to assess its spontaneous modulation. J Physiol 2005,
565(Pt 3):706–707.
10. Parati G, Di Rienzo M, Mancia G: How to measure baroreflex sensitivity:
from the cardiovascular laboratory to daily life. J Hypertens 2000, 18(1):7–19.
11. Ponchon P, Elghozi JL: Contribution of the renin-angiotensin and
kallikrein-kinin systems to short-term variability of blood pressure in
two-kidney, one-clip hypertensive rats. Eur J Pharmacol 1996,
297(1–2):61–70.
12. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM,
Mitchell GF, Sheffy J, Vita JA, Benjamin EJ: Cross-sectional relations of
digital vascular function to cardiovascular risk factors in the Framingham
Heart Study. Circulation 2008, 117(19):2467–2474.
13. Chin KY, Panerai RB: Comparative study of Finapres devices. Blood Press
Monit 2012, 17(4):171–178.
14. Pinna GD, Maestri R: New criteria for estimating baroreflex sensitivity
using the transfer function method. Med Biol Eng Comput 2002,
40(1):79–84.
15. Guelen I, Westerhof BE, Van Der Sar GL, Van Montfrans GA, Kiemeneij F,
Wesseling KH, Bos WJ: Finometer, finger pressure measurements with the
possibility to reconstruct brachial pressure. Blood Press Monit 2003,
8(1):27–30.
16. Guelen I, Westerhof BE, van der Sar GL, van Montfrans GA, Kiemeneij F,
Wesseling KH, Bos WJ: Validation of brachial artery pressure reconstruction
from finger arterial pressure. J Hypertens 2008, 26(7):1321–1327.
17. Schutte AE, Huisman HW, van Rooyen JM, Malan NT, Schutte R: Validation
of the Finometer device for measurement of blood pressure in black
women. J Hum Hypertens 2004, 18(2):79–84.
18. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA: The AUDIT alcohol
consumption questions (AUDIT-C): an effective brief screening test for
problem drinking. Ambulatory Care Quality Improvement Project
(ACQUIP). Alcohol Use Disorders Identification Test. Arch Intern Med 1998,
158(16):1789–1795.
19. La Fountaine MF, Wecht JM, Spungen AM, Bauman WA: Intra-inter visit
reproducibility of short-term linear and nonlinear measurement of heart
rate variability in tetraplegia and neurologically intact controls. Physiol
Meas 2010, 31(3):363–374.
20. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Sever PS,
Poulter NR: Prognostic significance of visit-to-visit variability, maximum
systolic blood pressure, and episodic hypertension. Lancet 2010,
375(9718):895–905.
doi:10.1186/1471-2261-14-180
Cite this article as: Linder et al.: Finger volume pulse waveforms
facilitate reliable assessment of heart rate variability, but not blood
pressure variability or baroreflex function. BMC Cardiovascular Disorders
2014 14:180.
